Pharmaceutical News and Articles

Humanetics Corporation Announces Positive Phase 2 Clinical Trial Results in COVID-19 Study Aimed at Improving Pulmonary Function

Humanetics Corporation (Humanetics) announced today the results of its Phase 2 clinical trial of BIO 300 Oral Suspension (BIO 300) for the mitigation of impaire

Tris Pharma Announces Positive Results from ALLEVIATE-1 Phase 3 Clinical Trial of Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain

MONMOUTH JUNCTION, NJ, January 22, 2025 Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from it

Why Sparkling Water May (Or May Not) Help You Lose Weight

THURSDAY, Jan. 23, 2025 Chalk up a partial win for health influencers who tout the slimming benefits of sparkling waters. New research out of Japan affirms that

Adults With ADHD Linked To Shorter Life Expectancy, Study Shows

Adults with attention deficit hyperactivity disorder, otherwise known as ADHD, may face a shorter life expectancy than their peers. On average, men with ADHD di

Injurious Falls Common in Last Years of Life With COPD

Injurious falls are common among people with chronic obstructive pulmonary disease (COPD) in the two years before death, with some medications tied to higher fa

Incidence, Prevalence of Peripartum Mental Illness Increased for Mothers With MS

Mothers with multiple sclerosis (MS) have an elevated incidence and prevalence of peripartum mental illness, according to a study published online Jan. 22 in Ne

Risk for All-Cause Mortality Lower With High Muscle Strength, Fitness in Cancer

For patients diagnosed with cancer, high muscle strength and cardiorespiratory fitness (CRF) are associated with a reduced risk for all-cause mortality, accordi

Perioperative Chemo With FLOT Ups Survival in Resectable Esophageal Cancer

For patients with resectable esophageal adenocarcinoma, perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) leads to imp

Fewer Bleeding Events Seen With Abelacimab Than Rivaroxaban in A-Fib

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding events than rivaroxaban in patients with atrial

Stealth BioTherapeutics Announces PDUFA Action Date Extension for Elamipretide to Treat Patients with Barth Syndrome